When hip replacement feels inevitable

For many people reaching the later stages of hip osteoarthritis, the conversation with their surgeon eventually turns to hip replacement — and for good reason. Total hip arthroplasty reliably reduces pain and restores mobility, and approximately 58% of implants are estimated to last 25 years. The difficulty is what that figure implies: a meaningful proportion of patients, particularly those operated on in their forties or fifties, will eventually need a revision procedure. Revision hip surgery carries greater technical complexity and higher complication risk than the first operation, so every year that replacement can be responsibly deferred matters.

The clinical gap is sharpest for patients who have advanced joint wear — Kellgren-Lawrence Grade IV osteoarthritis, involving diffuse cartilage loss across the whole joint surface — but who are not yet ready or suitable for surgery. They may be too young to accept the likely need for revision, medically unfit for general anaesthetic, or simply unwilling to proceed before exhausting non-operative options. Standard injection therapies leave this group underserved: a 2025 systematic review and meta-analysis found that intra-articular corticosteroids provide no statistically significant symptomatic improvement over placebo in hip osteoarthritis, and high molecular weight hyaluronic acid shows no significant advantage over comparator treatments.

A bridge treatment for this group does not aim to restore the hip to a pre-arthritic state. Its more modest — and clinically realistic — goal is to reduce pain and preserve functional quality of life in the joint that remains. This article examines what Liquid Cartilage™ offers as one such candidate, and how robust the current evidence base for its use in the hip actually is.

How Liquid Cartilage works inside the hip joint

Liquid Cartilage™ is the clinical brand name for ChondroFiller®, a CE-marked Class III medical implant composed of murine-derived Type I collagen. For hip patients, the current treatment pathway is an ultrasound-guided outpatient injection: the collagen scaffold is placed directly into the hip joint under image guidance, without surgery or general anaesthetic.

Once inside the joint, the solution self-gels on contact with synovial fluid, spreading across the articular surface to provide a temporary structural matrix. The biological process this triggers is known as acellular matrix-induced chondrogenesis — in plain terms, the scaffold gives the body's own cells a structure to grow into. Because it contains no cells of its own, the implant works by recruiting the patient's progenitor cells from the surrounding synovium and subchondral bone. These cells migrate into the collagen framework, where they can differentiate and begin producing cartilage-forming proteins — collagen and glycosaminoglycans — as the scaffold gradually biodegrades. The treatment supports the body's own repair processes rather than delivering pre-formed tissue.

A 2025 human ex vivo osteochondral model demonstrated that ChondroFiller® alone produced a 2.4-fold increase in DNA content by day 14, confirming measurable cell recruitment at the scaffold site.

For the hip specifically, the injection pathway is designed for patients with diffuse joint wear — including advanced osteoarthritis — where whole-surface coverage is the priority. A separate surgical pathway exists for contained focal defects and combines ChondroFiller® with mesenchymal stem cell co-delivery under general anaesthetic; that procedure falls outside the scope of the outpatient injection service described here. The distinction matters clinically, because patient selection, recovery, and goals differ significantly between the two approaches.

What the evidence actually shows

The strongest direct signal for ChondroFiller® in the hip comes from clinical series and product documentation rather than published randomised trials. Hip patients treated via the outpatient injection pathway have shown approximately a 30-point improvement in modified Harris Hip Score (mHHS) — a validated measure of hip pain and function. That figure sits within the range seen in hip cartilage preservation studies, but should be read as expert clinical series data rather than the output of a controlled trial.

The published mechanistic evidence, described in the previous section, supports the biological rationale at a cellular level. The strongest published outcome data for ChondroFiller® itself comes from a prospective clinical study conducted in the wrist: treated joints showed significantly superior cartilage quality at follow-up arthroscopy versus untreated controls — median Outerbridge grade 1.5 versus 3.0 (p=0.006) and ICRS grade 1 versus 3 (p=0.002). The authors noted that further long-term studies in large joints are needed. This is a meaningful signal for the implant's cartilage-quality effect, but the wrist and hip operate in very different biomechanical environments; the data cannot be transposed directly onto hip outcomes.

For hip-specific scaffold evidence, the closest published comparator is BioCartilage® — an allograft extracellular matrix scaffold combined with PRP, applied to Outerbridge grade IV hip chondral defects. At two years, 89.3% of 91 patients reached a clinically meaningful improvement threshold, and only 10.9% converted to total hip arthroplasty. Five-year follow-up data (n=79, mean follow-up 69.9 months) showed durable functional benefit across all outcome measures (p<0.05). This is analogous scaffold evidence: it supports the principle that scaffold-based cartilage treatment can protect hip function and reduce conversion to arthroplasty, but BioCartilage® is a different product delivered by a different route, and these findings cannot be attributed to ChondroFiller® directly.

No peer-reviewed randomised controlled trial of ChondroFiller® or Liquid Cartilage™ in the hip has been published. The evidence base currently rests on expert clinical series, product documentation, and mechanistic science. That is not unusual for a CE-marked implant at this stage of clinical adoption, but it means that both patients and clinicians are working from a developing body of evidence rather than a settled one.

How it compares to other hip injection options

A 2025 systematic review and meta-analysis found that intra-articular corticosteroid injections for hip osteoarthritis produced no statistically significant symptomatic improvement over placebo — a finding that underlines the limits of one of the most commonly used hip injection treatments. Corticosteroids retain a legitimate role in short-term flare control or pre-procedure inflammation management, but the evidence does not support them as an ongoing joint-management strategy.

High molecular weight hyaluronic acid (HA) viscosupplementation occupies a different position. Two 2024–2025 meta-analyses found no statistically significant differences in pain or functional outcomes between HMWHA and comparator treatments — including corticosteroid, PRP, and saline — in hip OA. Patients do, on average, improve from their pre-treatment baseline at one to six months, which is why HA continues to be used. The honest characterisation, though, is palliative and symptom-directed: it provides temporary lubrication and some pain relief, but does not restore or support cartilage tissue.

Regenerative approaches using adipose-derived mesenchymal stem cells have produced encouraging early results in the hip. One 2025 case report documented histologically confirmed hyaline-like cartilage in a previously degenerated area at 12 months — but the patient required total hip arthroplasty when symptoms recurred at 18 months, illustrating the durability gap that current published hip data reveal for cell-based approaches.

Arthrosamid® — a polyacrylamide hydrogel (PAAG) — is sometimes listed alongside ChondroFiller as an injection option for hip pain, and it appears in that context at Lincolnshire Hip. The two treatments are not interchangeable. Arthrosamid is a non-regenerative, permanent hydrogel filler; it cushions the joint but does not recruit cells or support endogenous tissue repair. ChondroFiller's proposed advantage is mechanistic: a biodegradable scaffold that promotes the body's own repair processes rather than permanently occupying joint space. Whether that advantage translates to meaningfully superior hip outcomes over the longer term remains an open question — hip-specific controlled trial data for ChondroFiller do not yet exist in the published literature.

Which hip patients are most likely to benefit

The injection pathway starts from a different premise than focal cartilage repair surgery: there is no minimum defect size and no upper age limit. Patients with Kellgren-Lawrence Grade IV hip osteoarthritis — the most advanced radiological stage — have been treated via this route, which places it well outside the eligibility criteria for focal repair techniques that require a contained, size-limited lesion in otherwise healthy surrounding cartilage.

For that advanced group, the framing at consultation matters. The ChondroFiller® injection for diffuse hip wear is not being deployed to rebuild cartilage architecture; it is intended to provide viscoelastic cushioning, reduce pain, and extend functional capacity — a bridge strategy, not a structural cure. Patients who understand that distinction from the outset tend to set more realistic expectations about what success looks like.

The candidates who benefit most are reasonably identifiable. Someone in their late forties or fifties with Grade IV OA, diffuse wear on MRI, and a goal of deferring hip replacement for several years while addressing general fitness is a stronger candidate than someone with severe joint deformity, minimal residual joint space, or rapidly progressive symptoms — where total hip arthroplasty is likely the more appropriate next step. Patients with significant surgical risk from cardiovascular disease or other comorbidities represent a further group for whom a bridge injection carries particular clinical logic.

Imaging — X-ray and MRI — is required before selecting an approach. The MRI pattern of wear and residual cartilage thickness influence both whether the injection is appropriate and which delivery approach is selected; not every presentation of hip pain maps to ChondroFiller®.

One practical consideration affects anyone for whom an immediate return to full hip loading is essential. A 2024 biomechanical study found that ChondroFiller has initial mechanical instability under full cyclic load, and full weight-bearing should be delayed until scaffold integration is achieved. Where a patient's occupation or sport makes that rehabilitation window unworkable, this is a relevant factor to explore at the assessment stage.

What the treatment involves, from injection to recovery

The appointment itself is straightforward. ChondroFiller® is delivered under ultrasound guidance as an outpatient procedure — no general anaesthetic, no surgical incision, no hospital admission. Once injected into the hip joint, the collagen solution self-gels and conforms to the cartilage surface within minutes of placement.

A period of reduced hip loading follows while the scaffold settles. As discussed in the previous section, full weight-bearing is introduced gradually under clinical guidance rather than resumed straight away — this is a managed integration phase, not a complication.

The biological process — cell recruitment, collagen deposition, tissue-level change — takes weeks to months rather than days. Patients who notice little difference in the first few weeks have not necessarily had a poor response; the scaffold's activity precedes any functional shift that becomes noticeable. Outcome measures taken too early can give a misleading picture of whether the hip is responding.

Follow-up assessments track functional progress and inform next steps. Not every hip responds identically, and the post-injection picture — drawn from patient-reported outcome scores and, where relevant, imaging — helps clarify whether the joint has stabilised or whether further planning is needed.

Lincolnshire Hip is part of the MSK Doctors group and accepts patients without referral, with appointments available in Sleaford and Grantham. Before a booking decision, what matters most is understanding what this injection is designed to do: provide a managed integration phase, support a biological repair process measured in months, and serve as a considered bridge for patients who are not yet ready for hip replacement — a realistic strategy for extending functional life in the joint, rather than an immediate fix.

1. [1] Development of an Ex Vivo Osteochondral Biomimetic Platform for Mechanistic Investigation of Cartilage Regeneration. (2025). https://doi.org/10.3390/ijms262311759 https://doi.org/10.3390/ijms262311759
2. [2] Cartilage reconstruction using Chondrofiller in intra-articular distal radius fractures. (2025). https://doi.org/10.1186/s42836-025-00333-y https://doi.org/10.1186/s42836-025-00333-y
3. [3] Influence of cartilage defects and a collagen gel on integrity of corresponding intact cartilage: a biomechanical in-vitro study. (2024). https://doi.org/10.1007/s00402-024-05530-z https://doi.org/10.1007/s00402-024-05530-z
4. [4] Poster 104: Rates of Achieving Meaningful Outcomes and Predictors of Clinical Failure 5-Years After Undergoing Microfracture Augmented with Allograft Cartilage For Treatment of Hip Chondral Defects. (2025). https://doi.org/10.1177/2325967125s00203 https://doi.org/10.1177/2325967125s00203
5. [5] Editorial Commentary: Hip Chondral Defect Treatment Requires Cells, Signal, and Scaffold. (2022). https://doi.org/10.1016/j.arthro.2022.06.007 https://doi.org/10.1016/j.arthro.2022.06.007
6. [6] FP8.6 Rates of Achieving Meaningful Outcomes 2-Year After Undergoing Microfracture Augmented with Allograft Cartilage and Autologous PRP For Hip Chondral Defects. (2025). https://doi.org/10.1093/jhps/hnaf011.072 https://doi.org/10.1093/jhps/hnaf011.072